NLRP3 and neuroblastoma: This context‐dependent duality presents a fundamental therapeutic challenge: the same molecular pathway (e.g., NLRP3/caspase‐1/GSDMD) that must be inhibited to treat neuropathic pain is the one that should be strategically induced to treat neuroblastoma, necessitating a precision medicine approach.